Belite Bio
BLTE
81 hedge funds and large institutions have $1.44B invested in Belite Bio in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
8% more funds holding
Funds holding: 75 → 81 (+6)
1% more capital invested
Capital invested by funds: $1.42B → $1.44B (+$19.4M)
0.46% more ownership
Funds ownership: 23.17% → 23.63% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$60.7M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$38.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$28.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$18.5M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$83.3M |
| 2 |
Holocene Advisors
New York
|
-$37.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27M |
| 4 |
PA
Perceptive Advisors
New York
|
-$24.2M |
| 5 |
Millennium Management
New York
|
-$11.6M |
BLTE Hedge Fund Activity: Q2 2026 in Review
81 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q2 2026, worth a combined $1.44B — up 1.4% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BLTE positions and 16 closed out — a net gain of 6 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $60.7M. The largest seller was UBS Group, cutting an estimated $83.3M.
- 81 institutional investors held Belite Bio (BLTE) as of Q2 2026, up from 75 in Q1 2026.
- Funds reported $1.44B of Belite Bio stock for Q2 2026, up 1.4% quarter-over-quarter.
- 22 funds opened new Belite Bio positions in Q2 2026 and 16 closed out, a net change of +6 holders.
- The largest Belite Bio buyer in Q2 2026 was Maverick Capital, an estimated $60.7M added.
- The largest Belite Bio seller in Q2 2026 was UBS Group, an estimated $83.3M sold.
Based on aggregated 13F filings for Q2 2026.